Hemolung RAS Registry Program

NCT01855815 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 99

Last updated 2019-01-28

No results posted yet for this study

Summary

The purpose of the Hemolung RAS Registry Program is to collect retrospective, de-identified, standard of care data following the commercial use of the Hemolung RAS.

Conditions

  • Acute Hypercapnic Respiratory Failure

Sponsors & Collaborators

  • Alung Technologies

    lead INDUSTRY

Principal Investigators

  • Nausherwan Burki, MD, PhD · ALung Technologies, Inc.

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2019-12-31
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01855815 on ClinicalTrials.gov